#TalkingRegMed 7: Cell therapy and big pharma with Sven Kili, GSK
In this exclusive video, Sven Kili, VP and Head of Cell & Gene Therapy Development, GSK, explains why rare diseases are so amenable to treatment with cell therapies.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.